Pasithea Therapeutics Corp. Statistics
Share Statistics
Pasithea Therapeutics Corp. has 1.27M shares outstanding. The number of shares has increased by -94.99% in one year.
Shares Outstanding | 1.27M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.08% |
Owned by Institutions (%) | n/a |
Shares Floating | 1.02M |
Failed to Deliver (FTD) Shares | 1.29K |
FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 11.58K, so 0.91% of the outstanding shares have been sold short.
Short Interest | 11.58K |
Short % of Shares Out | 0.91% |
Short % of Float | 1.13% |
Short Ratio (days to cover) | 0.32 |
Valuation Ratios
The PE ratio is -0.59 and the forward PE ratio is -4.73.
PE Ratio | -0.59 |
Forward PE | -4.73 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | 0.4 |
P/FCF Ratio | -0.69 |
PEG Ratio | n/a |
Enterprise Valuation
Pasithea Therapeutics Corp. has an Enterprise Value (EV) of -.
EV / Earnings | null |
EV / Sales | null |
EV / EBITDA | null |
EV / EBIT | null |
EV / FCF | null |
Financial Position
The company has a current ratio of 6.34, with a Debt / Equity ratio of 0.
Current Ratio | 6.34 |
Quick Ratio | 6.34 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.68% and return on capital (ROIC) is -68.05%.
Return on Equity (ROE) | -0.68% |
Return on Assets (ROA) | -0.61% |
Return on Capital (ROIC) | -68.05% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.00M |
Employee Count | 8 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -61.86% in the last 52 weeks. The beta is 0.82, so Pasithea Therapeutics Corp.'s price volatility has been higher than the market average.
Beta | 0.82 |
52-Week Price Change | -61.86% |
50-Day Moving Average | 3.63 |
200-Day Moving Average | 5.38 |
Relative Strength Index (RSI) | 32.28 |
Average Volume (20 Days) | 964.29K |
Income Statement
In the last 12 months, Pasithea Therapeutics Corp. had revenue of $0 and earned -$15.96M in profits. Earnings per share was $-12.65.
Revenue | 0 |
Gross Profit | -648.45K |
Operating Income | -15.98M |
Net Income | -15.96M |
EBITDA | -15.33M |
EBIT | - |
Earnings Per Share (EPS) | -12.65 |
Balance Sheet
The company has $16.33M in cash and $81.68K in debt, giving a net cash position of $16.25M.
Cash & Cash Equivalents | 16.33M |
Total Debt | 81.68K |
Net Cash | 16.25M |
Retained Earnings | -35.32M |
Total Assets | 18.64M |
Working Capital | 9.12B |
Cash Flow
In the last 12 months, operating cash flow was -$13.43K and capital expenditures -$34.3, giving a free cash flow of -$13.46M.
Operating Cash Flow | -13.43K |
Capital Expenditures | -34.3 |
Free Cash Flow | -13.46M |
FCF Per Share | -10.67 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
Gross Margin | 0% |
Operating Margin | 0% |
Pretax Margin | 0% |
Profit Margin | 0% |
EBITDA Margin | n/a% |
EBIT Margin | n/a% |
FCF Margin | n/a% |
Dividends & Yields
KTTA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -473.78% |
FCF Yield | -397.31% |
Analyst Forecast
Currently there are no analyst rating for KTTA.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 2, 2024. It was a backward split with a ratio of 1:20.
Last Split Date | Jan 2, 2024 |
Split Type | backward |
Split Ratio | 1:20 |
Scores
Altman Z-Score | 580.81 |
Piotroski F-Score | 3 |